Povetacicept · OLYMPUS Phase 3
Vertex says Phase 2B completed and Phase 3 is underway in pMN. This is not the IgAN RAINIER interim result or the IgAN FDA application. povetacicept — phase 2, phase 3 study in Primary Membranous Nephropathy. NCT07204275 lists Proportion of Participants with Complete Clinical Remission Definition 1 (CR1) as a primary outcome (At Week 104). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2028-12-29 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Phase 3 pMN monitor — date unconfirmed
Potential outcome market
Will povetacicept meet the prespecified primary endpoint in NCT07204275 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.